Hematologic Malignancies and Cellular Therapy

Danielle Marie Brander, MD

Assistant Professor of Medicine

Member of the Duke Cancer Institute

Campus mail 2400 Pratt St Suite 5000, Durham, NC 27710

Phone (919) 668-1000

Email address danielle.brander@duke.edu

In Their Words

Education and Training

Resident, Internal Medicine, Duke University School of Medicine, 2007 - 2010
M.D., Duke University School of Medicine, 2007

Grants

A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects with Relapsed or Refractory B-cell Malignancies
AN OPEN LABEL PHASE Ia/b DOSE ESCALATION FOLLOWED BY DOSE EXPANSION SAFETY AND TOLERABILITY TRIAL OF CAP 100, A HUMANIZED C C CHEMOKINE RECEPTOR 7 ANTIBODY, ADMINISTERED AS MONOTHERAPY IN SUBJECTS WITH R/R CHRONIC LYMPHOCYTIC LEUKEMIA
A Phase 3, Randomized study of Zanubrutinnig (BGB-3111) compared with Ibrutinig in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
A Phase 1, Open-label, study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies after failure of prior standard therapies
BGB-3111-304 An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1a/1b Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, CTRM-505 and DTRM-555, in Patients with Chronic Lymphocytic Leukemia or Other B-Cell Lymphomas
An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently receiving Treatment on Ublituximab and/or TGR-1202 Trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
DFCI Obinutuzumab and Ibrutinib Protocol # 15-283
A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia.
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or P13K-Delta Inhibitor Therapy
A Multi¿Center, Open¿Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)
Phase III study of ACP-196 vs Ibrutinib in High Risk CLL

Publications

Hu, Rachel, Wei Wei, Agrima Mian, Kristen Gonter-Aubin, Charlene Kabel, Anthony Mato, Deborah M. Stephens, et al. “Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.” Eur J Haematol 108, no. 5 (May 2022): 379–82. https://doi.org/10.1111/ejh.13744.

PMID

35043475

Full Text

Mato, Anthony R., Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, et al. “Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).” Clin Cancer Res 28, no. 4 (February 15, 2022): 603–8. https://doi.org/10.1158/1078-0432.CCR-21-1237.

PMID

34789482

Full Text

Kleinstern, Geffen, J Brice Weinberg, Sameer A. Parikh, Esteban Braggio, Sara J. Achenbach, Dennis P. Robinson, Aaron D. Norman, et al. “Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.” Leukemia 36, no. 1 (January 2022): 119–25. https://doi.org/10.1038/s41375-021-01344-9.

PMID

34285341

Full Text

Davids, Matthew S., Owen A. O’Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, et al. “Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.” Blood Adv 5, no. 23 (December 14, 2021): 5332–43. https://doi.org/10.1182/bloodadvances.2021005132.

PMID

34547767

Full Text

MacDonald, Grace, Andrea Sitlinger, Michael A. Deal, Erik D. Hanson, Stephanie Ferraro, Carl F. Pieper, J Brice Weinberg, Danielle M. Brander, and David B. Bartlett. “A pilot study of high-intensity interval training in older adults with treatment naïve chronic lymphocytic leukemia.” Sci Rep 11, no. 1 (November 30, 2021): 23137. https://doi.org/10.1038/s41598-021-02352-6.

PMID

34848750

Full Text

Stephens, Deborah M., Ken Boucher, Elizabeth Kander, Sameer A. Parikh, Erin M. Parry, Mazyar Shadman, John M. Pagel, et al. “Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.” Haematologica 106, no. 11 (November 1, 2021): 2845–52. https://doi.org/10.3324/haematol.2020.256388.

PMID

33054118

Full Text

Ruppert, Amy S., Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steven Coutre, Jennifer R. Brown, et al. “Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.” Leukemia 35, no. 10 (October 2021): 2854–61. https://doi.org/10.1038/s41375-021-01342-x.

PMID

34274940

Full Text

Ma, Shuo, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, et al. “Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.” Blood 138, no. 10 (September 9, 2021): 836–46. https://doi.org/10.1182/blood.2020009578.

PMID

34115103

Full Text

Gordon, Max J., Andy Kaempf, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, et al. “The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.” Clin Cancer Res 27, no. 17 (September 1, 2021): 4814–24. https://doi.org/10.1158/1078-0432.CCR-20-3993.

PMID

34168050

Full Text

Mato, Anthony R., Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, et al. “Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.” Blood 137, no. 20 (May 20, 2021): 2817–26. https://doi.org/10.1182/blood.2020007376.

PMID

33259589

Full Text

Danielle Marie Brander, MD

Education and Training

Grants

Publications

Pages